je.st
news
Tag: therapeutics
Knight Therapeutics reacquires leishmaniasis drug Impavido
2016-03-16 02:20:59| Agriculture - Topix.net
Jonathan Ross Goodman is president and CEO and Jeffrey Kadanoff is CFO of Knight Therapeutics. The Montreal drug distributor has bought back the distribution rights to Impavido, a treatment for the rare parasitic disease leishmaniasis.
Tags: drug
knight
therapeutics
reacquires
Cytori Therapeutics posts 4th-quarter loss of $2.8 million
2016-03-04 00:40:55| Biotech - Topix.net
The San Diego-based company said it had a loss of 2 cents per share. Losses, adjusted for non-recurring gains, were 3 cents per share.
Tags: posts
million
loss
therapeutics
United Therapeutics: An Undervalued Biotech That Dominates Its Field
2016-03-01 16:32:35| Biotech - Topix.net
United Therapeutics is a specialty pharmaceutical company, focusing on very small patient indications that allow it to win orphan drug designation, which protects its products for long periods of time and allows premium pricing. Specifically, United focuses on drugs that extend the lifespan for suffers of pulmonary arterial hypertension , a dangerous disease of high lung blood pressure that, sadly, is fatal to most sufferers.
Tags: united
field
biotech
dominates
Esperion Therapeutics Inc (ESPR) to Post FY2015 Earnings of ($2.36)...
2016-02-29 13:29:43| Biotech - Topix.net
Esperion Therapeutics Inc - Lake Street Capital decreased their FY2015 earnings per share estimates for shares of Esperion Therapeutics in a research note issued to investors on Thursday, according to Zacks Investment Research . Lake Street Capital analyst C. Byrnes now forecasts that the brokerage will earn per share for the year, down from their prior forecast of .
Tags: post
earnings
therapeutics
fy2015
Catalent Biologics And Cerenis Therapeutics Announce Phase III Trial Of CER-001 In Europe And North America Leveraging GPEx Cell Line Technology
2016-02-03 03:16:56| drugdiscoveryonline Home Page
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, consumer health and animal health products, today announced that Cerenis Therapeutics has advanced its leading clinical candidate, CER-001, into Phase III clinical studies across Europe and North America
Tags: line
technology
north
iii
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] next »